Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Costa

Showing results (31-40 of 1,083) with videos related to

Pageof 109
Sort By:
European Journal of Pharmacology|April 27, 2000
Changes in rat brain energetic metabolism after exposure to anandamide or Delta(9)-tetrahydrocannabinolB Costa, M Colleoni
Medicina Clinica|March 12, 1994
[Drug consumption in diabetes mellitus (IV). The utilization of reactive material and systems for assessing blood glucose control from the viewpoint of primary care. The Group for the Study of Diabetes in Tarragona (GEDT)]B Costa, M Huguet
Pharmacoeconomics|June 7, 1994
Cost implications of wastage of drugs: focus on insulinB Costa, M Belmonte
Zhongguo Yao Li Xue Bao = Acta Pharmacologica Sinica|February 24, 2001
SR141716A induces in rats a behavioral pattern opposite to that of CB1 receptor agonistsB Costa, M Colleoni
Case Reports in Oncology|December 28, 2017
Occult Breast Carcinoma Presenting as Scalp MetastasisRicardo L B Costa, Rubens B Costa-Filho, Marilin Rosa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2008
Response of intracranial metastases to epidermal growth factor receptor tyrosine kinase inhibitors: it may all depend on EGFR mutationsDaniel B Costa, Susumu Kobayashi
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 4, 2019
From Hope to Reality: Durable Overall Survival With Immune Checkpoint Inhibitors for Advanced Lung CancerDeepa Rangachari, Daniel B Costa
British Journal of Cancer|January 17, 2007
Are exon 19 deletions and L858R EGFR mutations in non-small-cell lung cancer clinically different?D B Costa, S Kobayashi
Lancet (London, England)|February 17, 2009
Gefitinib plus docetaxel in non-small-cell lung cancerDaniel B Costa, Susumu Kobayashi
Translational Cancer Research|January 8, 2019
Moving the mountain in advanced non-small-cell lung cancer: evolving immunotherapies for a dire diseaseDeepa Rangachari, Daniel B Costa
Pageof 109

Showing results (31-40 of 1,083) with videos related to

Sort By:
Pageof 109
European Journal of Pharmacology|April 27, 2000
Changes in rat brain energetic metabolism after exposure to anandamide or Delta(9)-tetrahydrocannabinolB Costa, M Colleoni
Medicina Clinica|March 12, 1994
[Drug consumption in diabetes mellitus (IV). The utilization of reactive material and systems for assessing blood glucose control from the viewpoint of primary care. The Group for the Study of Diabetes in Tarragona (GEDT)]B Costa, M Huguet
Pharmacoeconomics|June 7, 1994
Cost implications of wastage of drugs: focus on insulinB Costa, M Belmonte
Zhongguo Yao Li Xue Bao = Acta Pharmacologica Sinica|February 24, 2001
SR141716A induces in rats a behavioral pattern opposite to that of CB1 receptor agonistsB Costa, M Colleoni
Case Reports in Oncology|December 28, 2017
Occult Breast Carcinoma Presenting as Scalp MetastasisRicardo L B Costa, Rubens B Costa-Filho, Marilin Rosa, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2008
Response of intracranial metastases to epidermal growth factor receptor tyrosine kinase inhibitors: it may all depend on EGFR mutationsDaniel B Costa, Susumu Kobayashi
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 4, 2019
From Hope to Reality: Durable Overall Survival With Immune Checkpoint Inhibitors for Advanced Lung CancerDeepa Rangachari, Daniel B Costa
British Journal of Cancer|January 17, 2007
Are exon 19 deletions and L858R EGFR mutations in non-small-cell lung cancer clinically different?D B Costa, S Kobayashi
Lancet (London, England)|February 17, 2009
Gefitinib plus docetaxel in non-small-cell lung cancerDaniel B Costa, Susumu Kobayashi
Translational Cancer Research|January 8, 2019
Moving the mountain in advanced non-small-cell lung cancer: evolving immunotherapies for a dire diseaseDeepa Rangachari, Daniel B Costa
Pageof 109